Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751
Year: 2020
Type: article
Abstract: ABT-751, a novel orally available antitubulin agent, is mainly eliminated as inactive glucuronide (ABT-751G) and sulfate (ABT-751S) conjugates. We performed a pharmacogenetic investigation of ABT-751 pharmacokinetics using in-vitro data to guide the selection of genes for genotyping in a phase I trial of ABT-751.
DOI: 10.17615/t5dn-za84
Authors: Sahelijo, Leonardo, Mirkov, Snezana, Bhathena, Anahita, Ramírez, Jacqueline, Adjei, Araba, Fleming, Gini F., Katz, David A., Das, Soma, Innocenti, Federico, Ratain, Mark J., Gordon, Gary B., Medina, Diane, Zhang, Wei, Xiong, Julia, Chiu, Yi-Lin, Obel, Jennifer, Carr, Robert A., Krivoshik, Andrew, Chen, Pei Xian, Moyer, Ann M., Weinshilboum, Richard M.
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W4301799562